Winter Stuart S, Ricci Jerec, Luo Li, Lovato Debbie M, Khawaja Hadya M, Serna-Gallegos Tasha, Debassige Natalie, Larson Richard S
Department of Pediatrics Division of Pediatric Hematology/Oncology, the University of New Mexico Health Sciences Center.
Health (Irvine Calif). 2013 May;5(5A):41-50. doi: 10.4236/health.2013.55A005.
In acute lymphoblastic leukemia (ALL), multidrug resistance is often mediated by ATPase Binding Cassette (ABC) proteins, which principally involve ABCB1 (multidrug resistance 1, ) and ABCC1 (multidrug resistance protein 1, ). However, direct comparisons between the differential effects of ABCB1 and ABCC1 have been difficult, since identical cell lines with differential expression of these transporters have not been developed.
In this study, we developed and compared the biological profiles of Jurkat cell lines that selectively over-expressed ABCB1 and ABCC1. Vincristine (VCR) plays an important role in the treatment of T-lineage ALL (T-ALL), and is often the first drug given to newly-diagnosed patients. Because of its importance in treatment, we provided escalating, sub-lethal doses of VCR to Jurkat cells, and extended our observations to expression profiling of newly diagnosed patients with T-ALL.
We found that VCR-resistant cells over-expressed ABCC1 nearly 30-fold. The calcein AM assay confirmed that VCR-resistant cells actively extruded VCR, and that ABCC1-mediated drug resistance conferred a different spectrum of multidrug resistance than other T-ALL induction agents. siRNA experiments that blocked ABCC1 export confirmed that VCR resistance could be reversed in vitro. Analyses of T-lymphoblasts obtained from 92 newly diagnosed T-ALL patients treated on Children's Oncology Group Phase III studies 8704/9404 showed that induction failure could be explained in all but one case by the over-expression of ABCB1 or ABCC1.
Taken together, these results suggest that over-expression of ABC transporters plays a contributing role in mediating treatment failure in T-ALL, and underscore the need to employ alternate treatment approaches in patients for whom induction failed or for those with relapsed disease.
在急性淋巴细胞白血病(ALL)中,多药耐药通常由ATP结合盒(ABC)蛋白介导,主要涉及ABCB1(多药耐药蛋白1,MDR1)和ABCC1(多药耐药相关蛋白1,MRP1)。然而,由于尚未开发出具有这些转运蛋白差异表达的相同细胞系,因此很难直接比较ABCB1和ABCC1的不同作用。
在本研究中,我们开发并比较了选择性过表达ABCB1和ABCC1的Jurkat细胞系的生物学特性。长春新碱(VCR)在T细胞系ALL(T-ALL)的治疗中起重要作用,通常是新诊断患者使用的第一种药物。由于其在治疗中的重要性,我们向Jurkat细胞提供递增剂量且低于致死剂量的VCR,并将我们的观察扩展到新诊断的T-ALL患者的表达谱分析。
我们发现VCR耐药细胞中ABCC1的过表达近30倍。钙黄绿素AM检测证实VCR耐药细胞可主动排出VCR,并且ABCC1介导的耐药赋予了与其他T-ALL诱导剂不同的多药耐药谱。阻断ABCC1转运的siRNA实验证实VCR耐药在体外可以逆转。对从儿童肿瘤学组III期研究8704/9404中接受治疗的92例新诊断T-ALL患者获得的T淋巴母细胞进行分析,结果显示除1例患者外,所有诱导失败病例均可通过ABCB1或ABCC1的过表达来解释。
综上所述,这些结果表明ABC转运蛋白的过表达在介导T-ALL治疗失败中起作用,并强调对于诱导失败或复发疾病的患者需要采用替代治疗方法。